ProQR Therapeutics (PRQR) Cash & Equivalents (2021 - 2025)

ProQR Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $159.7 million for Q4 2024.

  • For Q4 2024, Cash & Equivalents rose 24.77% year-over-year to $159.7 million; the TTM value through Dec 2024 reached $159.7 million, up 24.77%, while the annual FY2024 figure was $161.7 million, 25.7% up from the prior year.
  • Cash & Equivalents for Q4 2024 was $159.7 million at ProQR Therapeutics, up from $128.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $214.5 million in Q4 2021 and bottomed at $96.7 million in Q4 2022.
  • The 4-year median for Cash & Equivalents is $143.8 million (2024), against an average of $149.7 million.
  • The largest annual shift saw Cash & Equivalents tumbled 54.93% in 2022 before it soared 32.33% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $214.5 million in 2021, then plummeted by 54.93% to $96.7 million in 2022, then soared by 32.33% to $128.0 million in 2023, then rose by 24.77% to $159.7 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Cash & Equivalents are $159.7 million (Q4 2024), $128.0 million (Q4 2023), and $96.7 million (Q4 2022).